

## Zymosan A

Cat. No.:	HY-W250113		
CAS No.:	58856-93-2		
Target:	Biochemical Assay Reagents		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

# Zymosan A

### SOLVENT & SOLUBILITY

In Vitro	DMSO : 1.94 mg/mL (ultrasonic and warming and adjust pH to 4 with HCl and heat to 60°C)
----------	---

### BIOLOGICAL ACTIVITY

Description	Zymosan A (Zymosan A from <i>Saccharomyces cerevisiae</i> ) is a TLR2 agonist, that targeting TLRs can prevent and suppress IR-induced intestinal injury. Zymosan A exhibits a significant radioprotective effect, and protects IR-induced intestinal injury in mice. Zymosan A promotes the regeneration of intestinal stem cells (ISCs), after IR injury <sup>[1]</sup> .		
In Vivo	Zymosan A can be used in animal modeling to establish a mouse peritonitis model.		
	Zymosan A (25.0 mg/kg; IP at 12 and 2 h before IR) mitigates IR-induced intestinal injury in mice <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	20.0 Gy abdominal irradiation (ABI) model in mice <sup>[1]</sup>	
	Dosage:	25.0 mg/kg, dissolved in NS	
	Administration:	IP; injection at 12 and 2 h before IR	
	Result:	Significantly reduced the degree of bleeding and edema in the intestinal tissue.	

### REFERENCES

[1]. Du J, et al. Zymosan-A promotes the regeneration of intestinal stem cells by upregulating ASCL2. *Cell Death Dis.* 2022 Oct 20;13(10):884.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA